Mr. Scheinfeld has over 20 years experience investing in public and private companies and since 1999 has been a founder of investment funds that have funded or committed to fund over $3.0 billion.

Mr. Cope has over 20 years experience investing in public and private companies and focuses on private equity investments and life sciences investing.

Mr. Vogel since 1995 has worked with investment firms, managers and groups including extensive involvement in direct investments in the public equity markets as well secondary market investments.

Mr. Garcia brings a broad based knowledge of the private equity sector and public markets. As an investment professional since 1998, Mr. Garcia has been involved in the operational side of private equity and portfolio management in the securities industry.

Mr. Kerewich joined Lincoln Park Capital in 2011 and contributes a unique background and understanding of the capital markets for public companies. Since joining Lincoln Park Mr. Kerewich has been an integral part of the investment team, including analyzing and structuring public company investments.

Mr. Salchli joined LPC in 2014 as CTO and brings a diversity of experience in business, technology and the life sciences. Mr. Salchli evaluates technology investment opportunities and advises LPC private portfolio companies and emerging startups.

Dr. Davis joined Lincoln Park Capital in 2017 as a biotechnology analyst. Prior to joining the firm, he studied how gene regulatory networks control cellular behaviors during his doctoral work at the University of Chicago. His thesis culminated in multiple primary research publications, including perspectives on the trajectory of regenerative…

Mr. Palmer joined Lincoln Park Capital in 2015 as an Analyst. Before joining LPC, Mr. Palmer held several internship positions while attending DePaul University including as an investment intern at Saxony Capital Management, LLC an asset management firm, where he worked in portfolio analysis and client management.

Mr. Hogaboom joined the Lincoln Park Capital team in 2017 as an Analyst. Prior to, Mr. Hogaboom worked at Robert W. Baird on the Capital Markets Operations team assisting in Institutional Trading. While attending Marquette University, he worked as a valuation analyst intern with FV & FMV Valuation, Inc. as…

Dr. O’Brien joined Lincoln Park Capital in 2021 as a biotechnology analyst. Prior to joining, he developed proof-of-principle molecular computational devices to demonstrate and understand the computational capacity of biochemical systems as a graduate researcher at the University of Chicago’s Department of Physics (M.S 2017, Ph.D 2021).